Media & Resources

Partnership also to include efforts to strengthen the continent's disease-fighting capacity, pandemic readiness, and supply resilience.

Across four preclinical studies, Scripps Research, IAVI, and additional collaborators make headway in stimulating the rare antibodies needed to fight HIV.

The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI’s single dose Lassa fever vaccine candidate.

Memorandum of understanding targets gender equity, mentorship, and training to expand the power and influence of talented women in science.

Novel HIV vaccine candidate based on Gorilla adenoviral vector (GRAd-HIV) funded by the Bill & Melinda Gates Foundation to alleviate the disease burden and improve the lives of the millions who lack access to prevention options.

TB kills 1.3 million people a year and sickens more than 10 million people annually. A new TB vaccine is needed to reach the global End TB goals. MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB…

NEW YORK and TOKYO — October 13, 2023 — IAVI, a nonprofit scientific research organization, and Japan’s National Institute of Infectious Diseases (NIID), the primary infectious disease research institute funded by the Government of Japan, have signed a memorandum of understanding to strengthen their international cooperation for research and development (R&D) to control infectious diseases. Two…

NEW YORK — JULY 6, 2023 — IAVI is pleased to announce a new award has been granted by the German government to help support the late-stage development of a promising tuberculosis (TB) vaccine candidate, MTBVAC. The German Federal Ministry of Education and Research (BMBF) through the KfW Development Bank has committed to contribute €9.2…